Rebyota Market Report 2026

Rebyota Market Overview

• The Rebyota market growth in the historic period has been driven by high recurrence rates of c difficile infection, limitations of antibiotic only treatments • Market expansion is supported by rising incidence of recurrent cdi, expanding regulatory support for microbiome drugs • Growth Driver: Impact Of Rising Antibiotic Utilization On The Growth Of The Rebyota Market • Market Trend: Leading Companies In The Rebyota Market Advancing Microbiome Therapeutics For Recurrent C. Diff Infections • North America was the largest region in 2025.

What Is Covered Under Rebyota Market?

Rebyota is a treatment derived from gut microbiota for the prevention or treatment of recurring Clostridioides difficile infection (rCDI). It works by restoring the balance of gut microbiota disrupted by previous infections or antibiotic treatments. The main formulations of rebyota are rectal suspension and oral capsules. Rectal suspension refers to a form of treatment for Clostridioides difficile infections (CDI), specifically designed for patients who may not be able to tolerate or respond to oral therapies. The clinical indication are colorectal cancer, diabetes mellitus, inflammatory bowel disease, irritable bowel syndrome. These are distributed by various distribution channels such as direct sales, pharmacies, and online platforms and used by various end users such as healthcare facilities, and home healthcare.

What Is The Rebyota Market Growth Forecast?

The growth in the forecast period can be attributed to rising incidence of recurrent cdi, expanding regulatory support for microbiome drugs, growing adoption in gastroenterology practice, increased investment in microbiome research, improved patient outcomes driving uptake. Major trends in the forecast period include rising adoption of microbiota based therapies, increasing focus on recurrent c difficile infection prevention, growing acceptance of live biotherapeutic products, expansion of gut microbiome restoration treatments, improved clinical outcomes in antibiotic resistant infections.

Global Rebyota Market Segmentation

1) By Formulation: Rectal Suspension, Oral Capsules 2) By Distribution Channel: Direct Sales, Pharmacies, Online Platforms 3) By End User: Healthcare Facilities, Home Healthcare

What Are The Drivers Of The Rebyota Market?

The rising utilization of antibiotics is expected to drive the growth of the reboyta market going forward. Antibiotics are medications used to treat bacterial infections by killing bacteria or inhibiting their growth, essential for managing numerous infectious diseases. The increased use of antibiotics is attributed to factors such as population growth, rising infectious disease rates, and greater accessibility to healthcare. Rebyota, a fecal microbiota therapy, complements the use of antibiotics by restoring gut microbiota balance after disruptions caused by antibiotic treatments, addressing complications such as recurrent Clostridioides difficile infections. For instance, in April 2023, according to the Centers for Disease Prevention and Control, a US-based health organization, in 2023, U.S. community (retail) pharmacies dispensed approximately 251. million oral antibiotic prescriptions in outpatient settings, corresponding to a rate of 752 prescriptions for every 1,000 people. Therefore, the rising utilization of antibiotics drives the reboyta market. The increasing number of clinical trials is expected to propel the growth of the reboyta market going forward. The rising clinical trials are due to the increasing demand for innovative treatments, advancements in medical research, and the growing focus on personalized medicine. Reboyta plays a pivotal role in enhancing clinical trials by providing advanced data analytics and insights, enabling researchers to optimize trial designs, improve patient recruitment strategies, and streamline operations for more efficient and effective study outcomes. For instance, in May 2023, according to Xtalks, a Canada-based digital healthcare company, clinicalTrials.gov reported 452,604 clinical studies that were registered internationally as of May 17, 2023. Additionally, 64,838 studies out of the total number that have been registered are actively seeking participants. Therefore, the increasing number of clinical trials drives the reboyta market.

Key Players In The Global Rebyota Market

Major companies operating in the rebyota market are Ferring Pharmaceuticals

Global Rebyota Market Trends and Insights

Major companies operating in the rebyota market is leading advancements in innovative solutions such as microbiome-based live therapeutic to address unmet needs in the prevention of recurrent infections. Microbiome-based live therapeutics use live microorganisms to restore balance in the body's microbiome, aiming to improve health outcomes, particularly for gastrointestinal, immune, and skin conditions. For instance, in April 2024, Ferring Pharmaceuticals, a Switzerland-based company specializing in microbiome-based therapies and reproductive health, launched Rebyota in the US. This first-of-its-kind microbiota-based treatment leverages a single-dose live microbial suspension to restore gut microbiota and prevent recurrent C. diff infections, marking a transformative approach to addressing a critical global health challenge. This launch represents a pivotal moment for Ferring, as it expands its portfolio into new therapeutic areas, particularly in microbiome-based therapeutics. The introduction of Rebyota is part of Ferring's broader strategy to diversify its offerings and enhance its position in key therapeutic areas such as gastroenterology and immunology.

Regional Insights

North America was the largest region in the rebyota market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Rebyota Market?

The rebyota market consists of sales of standardized fecal microbiota transplant (FMT) products and microbiome-based therapies specifically designed to restore gut microbiota and prevent or treat recurring Clostridioides difficile infection (rCDI). Values in this market are ‘factory gate’ values, meaning the value of goods sold by the manufacturers or creators of the treatments, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the treatments.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Rebyota Market Report 2026?

The rebyota market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the rebyota industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.